Phase 3 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of signing consent.
• People who are willing and able to sign a consent form and follow all study requirements.
• People with a good general health and activity level (rated 0 or 1 on a standard medical scale), with no worsening in the 2 weeks before screening.
• People who have been confirmed by laboratory tissue testing to have a specific type of T-cell lymphoma (called PTCL), limited to these subtypes: PTCL-not otherwise specified (but not the skin-based form), ALK-positive anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, or T-follicular helper phenotype PTCL.
• People whose lymphoma responded (either fully or partially) to a first round of standard chemotherapy (such as CHOP, BV-CHP, or similar treatments), as measured by standard medical guidelines, and where the time between finishing that treatment and starting this trial is 3 months or less.
• People who are either over 65 years old and not suitable for a stem cell transplant, or 65 or under but have chosen not to have a stem cell transplant.
• People whose bone marrow and major organs (including liver, kidneys, and heart) are functioning at levels that meet the trial's specific laboratory requirements (confirm exact values with trial site).

Who may not be able to join:

• People whose lymphoma was at an early stage (Stage I) when first diagnosed.
• People who have received certain other experimental or cancer-fighting drugs within the past 30 days before the trial starts.
• People who have had standard chemotherapy within the past 21 days before the trial starts.
• People currently taking steroid medications above a low threshold dose within the past 7 days before the trial starts.
• People who have had major surgery or serious physical injury within the past 4 weeks, or who have planned surgery during the trial period.
• People who have received certain cancer-targeting antibody treatments (including brentuximab vedotin) within the past 4 weeks, radiation therapy within the past 3 weeks, or certain specialised antibody-linked treatments within the past 10 weeks.
• People who have previously been treated with a type of drug called a JAK or STAT3 inhibitor at any time.
• People who have received immunotherapy (such as checkpoint inhibitor treatments) within the past 28 days before the trial starts.
• People who have received a live or viral vector vaccine within the past 28 days before the trial starts.
• People who are currently taking blood-thinning or antiplatelet medications that cannot be safely stopped at least 7 days before the trial starts.
• People who are taking certain other medications that affect how the trial drug is processed by the body and that cannot be stopped at least 7 days before the trial starts (confirm specific medications with trial site).
• People with an active hepatitis C infection.
• People with hepatitis B virus levels above a certain threshold, or whose hepatitis B status does not meet the trial's safety requirements (confirm with trial site).
• People with a known HIV infection confirmed by testing.
• People with other serious uncontrolled health conditions or significant abnormal lab results that, in the treating doctor's judgement, would make participation unsafe or interfere with the study.
• People with a history of lung inflammation caused by a drug, or who currently have significant lung inflammation of this type.
• People who are pregnant or breastfeeding.
• People who are able to have children and are unwilling or unable to use effective contraception during treatment and for a set period after the last dose (confirm required timeframe with trial site).

Important: Always verify eligibility with the trial site directly before applying.